Recent news highlights Perrigo's Q2 2026 earnings surpassing revenue and earnings expectations, reaffirmation of FY26 outlook, and share price movements reflecting market reactions.

• Perrigo reported Q2 earnings with key metrics discussed, highlighting operational performance and financial results [N1].
• The company swung to earnings in Q2, reaffirmed its FY26 outlook, and experienced a surge in shares during pre-market trading [N2].
• Perrigo surpassed Q2 earnings and revenue estimates, indicating positive quarterly performance [N3].
• Earlier in 2026, Perrigo's Q1 earnings surpassed estimates while sales missed and both declined year-over-year [N6, N8].
• The company's share price declined by 9% since the last earnings report as of early June 2026 [N5].

Perrigo's broad and diversified product portfolio across self-care and specialty care categories, combined with its strategic initiatives to improve supply chain efficiency and operational effectiveness, supports sustainable business performance. The company's focus on consumer-led innovation and multiple price tiers enhances its ability to meet evolving consumer needs and preferences. Recent earnings reports indicate operational resilience with net income generation and reaffirmed outlook. The company's liquidity position and ongoing investments in key brands and efficiency programs provide a foundation for maintaining competitive advantage.

Perrigo faces risks from regulatory compliance challenges, including evolving FDA requirements and environmental regulations such as the EU Green Deal, which may increase costs and operational complexity. Supply chain dependencies on single-source suppliers and concentrated manufacturing facilities expose the company to disruption risks from geopolitical conflicts, pandemics, or natural disasters. Economic downturns, shifts in consumer behavior, and changes in the retail landscape could adversely affect demand and pricing power. Additionally, reputational risks from product issues or negative social media could impact brand strength and financial results. Ongoing restructuring and strategic initiatives carry execution risks and may not yield anticipated benefits.

Perrigo's moat is anchored in its position as a leading provider of store brand private label self-care products in North America and a diversified branded portfolio in Europe. The company's scale in manufacturing and supply chain, combined with consumer-led innovation and a broad product offering across multiple price tiers, supports its competitive positioning. Strategic initiatives aimed at supply chain efficiency and operational improvements further enhance its cost structure and market responsiveness. Strong customer relationships, including a significant customer representing nearly 13% of sales, contribute to revenue stability. However, reliance on single-source suppliers and concentrated manufacturing locations pose operational risks that could impact the moat's durability.

• Regulatory Compliance Risks: Perrigo is subject to complex and evolving regulations including FDA requirements, environmental laws such as the EU Green Deal, and emerging AI and cybersecurity regulations. Non-compliance or increased regulatory costs could adversely affect operations and reputation [S1].
• Supply Chain and Manufacturing Risks: The company relies on third-party suppliers, including single-source suppliers, and has concentrated manufacturing operations. Disruptions from geopolitical conflicts, pandemics, or natural disasters could materially impact production and delivery [S4, S5].
• Customer Concentration Risk: One significant customer accounted for 12.9% of net sales in 2025. Loss or adverse changes in this relationship could materially impact revenue [S3].
• Economic and Market Risks: Changes in economic conditions, consumer discretionary spending, retail landscape shifts, and consumer behavior could negatively affect sales and profitability [S6].
• Reputational and Product Risks: Issues with product safety, negative social media, or increased pharmacovigilance reporting could damage brand reputation and financial results [S4].
• Execution Risks of Strategic Initiatives: Ongoing restructuring and efficiency programs require management focus and investment. Failure to achieve anticipated benefits could adversely affect financial performance [S1].

• Perrigo Co plc is a leading pure-play self-care company with a history of over a century providing health and wellness solutions primarily in North America and Europe [S1].
• The company operates mainly in two segments: Consumer Self-Care Americas (U.S. and Canada) and Consumer Self-Care International (Europe and Australia) [S1].
• Perrigo's product portfolio includes store brand private label self-care products and branded products such as Opill®, Mederma®, Compeed®, ellaOne®, Solpadeine®, Jungle Formula®, and ACO® [S1].
• The company has transitioned to a category-based segment reporting structure with segments: Self Care (Upper Respiratory, Digestive Health, Pain & Sleep, Healthy Lifestyle), Specialty Care (Women's Health, Skin Health), Infant Formula, and All Other (including Oral Care and Dermacosmetics) [S19, S20].
• Perrigo's business strategy includes initiatives such as the Supply Chain Reinvention Program and Project Energize to improve supply chain efficiency and operational effectiveness [S1].
• The company focuses on consumer-led innovation, delivering products across multiple price and value tiers to improve access and choice for consumers [S1].
• Perrigo's financial snapshot as of June 27, 2026, shows cash and equivalents of $432.1 million, current assets of $2.45 billion, current liabilities of $1.05 billion, a current ratio of 2.32, and a cash ratio of 0.43, indicating liquidity [S2].
• For the quarter ended June 27, 2026, Perrigo reported net income of $74.5 million and basic earnings per share of $0.54 [S2].
• The company has a significant customer representing 12.9% of consolidated net sales for the year ended December 31, 2025, with no other customer exceeding 10% [S3].
• Perrigo's manufacturing operations are concentrated in a few locations, making it susceptible to disruptions from natural disasters, pandemics, or other events [S5].
• The company relies on third-party suppliers for raw materials and manufacturing, including some single-source suppliers, which poses supply chain risks [S4].
• Perrigo faces regulatory risks including compliance with FDA regulations, environmental regulations such as the EU Green Deal, and evolving AI and cybersecurity risks [S1, S8].
• The company has experienced increased production costs and expects higher compliance costs to continue [S4].
• Perrigo's financial results are influenced by economic conditions, retail landscape changes, consumer behavior, and discretionary consumer spending [S6].
• The company has ongoing restructuring programs and strategic initiatives aimed at cost reduction and operational improvements [S1].
• Recent news reports indicate Perrigo reported Q2 earnings with key metrics discussed, reaffirmed FY26 outlook, and shares surged in pre-market trading on August 5, 2026 [N1, N2, N3].
• Perrigo's Q2 earnings and revenue surpassed estimates according to recent news [N3].
• The company reported Q1 earnings that surpassed estimates but sales missed and both fell year-over-year [N6, N8].
• Perrigo's share price experienced a 9% decline since the last earnings report as of June 5, 2026 [N5].
• Perrigo pays dividends with yields pushing above 8% as of early 2026 [N15].